High dose Epirubicin id effective in measurable metastatic prostate cancer: a phase II study of the EORTC genitourinary group
| العنوان: | High dose Epirubicin id effective in measurable metastatic prostate cancer: a phase II study of the EORTC genitourinary group |
|---|---|
| المؤلفون: | W. G. Jones, Maurizio Brausi, Sophie D. Fosså, M.A. Lentz, A. Pawinski, Jean Pierre Droz, P.H.M. de Mulder, M. van Glabbeke |
| المصدر: | European Journal of Cancer, 31A, 1622-1626 European Journal of Cancer, 31A, 10, pp. 1622-1626 |
| سنة النشر: | 1995 |
| مصطلحات موضوعية: | Cancer Research, medicine.medical_specialty, Lymphoma, Nausea, medicine.medical_treatment, Phases of clinical research, Gastroenterology, Experimental diagnostics and therapy of malignancies, Prostate cancer, Internal medicine, medicine, Mucositis, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries), Chemotherapy, Blood Cells, Leukemia, business.industry, Bacterial Infections, medicine.disease, Combined Modality Therapy, Magnetic Resonance Imaging, Surgery, Prostate-specific antigen, Oncology, Mycoses, medicine.symptom, business, Infection, Progressive disease, Epirubicin, medicine.drug |
| الوصف: | 39 hormone-resistant prostate cancer patients with bidimensionally measurable metastatic lesions were given epirubicin 100 mg/m(2) intravenously every 3 weeks. One patient was ineligible and excluded from analyses. According to WHO criteria, 9 patients (24%) had a partial response, 16 patients (42%) had stable disease (including 3 patients (8%) with a partial response not confirmed 1 month later), 11 patients (29%) had progressive disease, and in 2 patients (5%) response was not evaluated. Toxicity was as expected. Fifty-five per cent of patients had WHO grade 3/4 toxicity for white blood cells, and 3% of patients grade 3 toxicity for platelets. Other toxicities included nausea and vomiting, mucositis and alopecia. 2 patients with pre-existing cardiac disease developed cardiotoxicity (1 grade 2, 1 grade 3). An attempt was made to correlate response with prostate specific antigen (PSA) measurements. A positive trend was seen, but 2 non-responding patients showed a > 50% decrease in value. |
| وصف الملف: | application/pdf |
| تدمد: | 0959-8049 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2deabbc442171b4ad0a7b6a1f0d6725 https://hdl.handle.net/2066/204865 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....c2deabbc442171b4ad0a7b6a1f0d6725 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 09598049 |
|---|